Impact on biomarker development
RELENT research aims not only at developing new research tools and technologies but also validating and implementing methods to measure disease activity and monitor treatment more accurately thus avoiding drug toxicity and side effects such as infections. Three SME partners (EMC, Hycult, Phenocell) with extensive experience in the generation of resources for basic and translational research, pathway discovery and development of clinical tests will provide necessary reagents. They will profit from direct access to and translation of results from RELENT research that will advance their R&D portfolio by generating new resources, like a catalogue of small compounds to inhibit autophagy or proteases by partner 10 (EMC), or immunological tests by partner 11 (Hycult) and a biorepository of iPSC lines from patients with the autoimmune diseases we investigate by partner 12 (Phenocell).
Delivering these resources to the scientific community of European and global markets will strengthen the strategic position and competitiveness of the RELENT SME partners and contribute to their growth.